The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells

International Journal of Cancer

Volumn 93, Issue 5, 2001, Pages 674-680

  Hönemann, Dirk ^c   Chatterjee, Manik ^b   Savino, Rocco ^b   Bommert, Kurt ^d   Burger, Renate ^b   Gramatzki, Martin ^d   Dörken, Bernd ^c   Bargou, Ralf C ^a,e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Istituto di Ricerche di Biologia Molecolare   (Italy)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e NONE   (Germany)

Author keywords

Bone marrow stromal cells; Drug resistance; IL 6; Multiple myeloma; SANT 7

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTAGONIST; RETINOIC ACID; SANT 7; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; STROMA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL DIVISION; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN-6; STROMAL CELLS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0035452345     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1388     Document Type: Article

References (36)

1. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone
2. Bone marrow microenvironment and the progression of multiple myeloma
3. Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells
4. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment
5. CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease
6. Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells
7. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma
8. Interleukin 6 is essential for in vivo development of B lineage neoplasms
9. Interleukin-6 family of cytokines and gp130
10. Impaired immune and acute-phase responses in interleukin-6-deficient mice
11. The critical role of interleukin-6, interleukin-1β and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma
12. Mechanisms of bone lesions in multiple myeloma
13. Rational design of a receptor super-antagonist of human interleukin-6
14. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death
15. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
16. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction
17. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites
18. Marrow stromal cells as stem cells for nonhematopoietic tissues
19. 3H]thymidine incorporation assay
20. Gp130 and ras mediated signaling in human plasma cell line INA-6: A cytokine-regulated tumor model for plasmacytoma
21. Interleukin-6 prevents dexamethasone-induced myeloma cell death
22. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells
23. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
24. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
25. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
26. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage
27. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth
28. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130
29. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130
30. A new type of cytokine receptor antagonist directly targeting gp130
31. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1)
32. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
33. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
34. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: Enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies
35. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study
36. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy